$Bob's and Jbem's Bitchin' Bios

[basssque]

BHAT is on fire, trading strong!!

[tmeier]

ONTX after offering going to move up. Time to load is now!

[tmeier]

I told you guys that ADXS was an easy double!It's well in its way!! Looking for 1.00 plus with multiple eoy Catalysts!!

[toomorrow]

$RELI - People will be kicking themselves for not buying shares when this is at $3.00 per share. . . tick tock.

Nasdaq bound in 2020.

[tmeier]

Time to load ADXS! Easy double here! Lots of catalysts upcoming!

[tmeier]

AGRX Gonna run into Oct. 30th Ad Com!! Don't miss out!!

[tmeier]

You loaded up on PTN? Going to explode next week!!

[tmeier]

When?

[toomorrow]

$LHGI - BIG NEWS COMING SOON!

[toomorrow]

$SIGO - NEWS! MANY AGAINST THIS TICKER, NOW THEY HAVE LICENSE IN TACT AND FILINGS COMING.

Sunset Island Group Announces Its Subsidiary Has Obtained Its Provisional Annual Cultivation License From The State Of California
SAN CLEMENTE, CA -- March 15, 2019 -- InvestorsHub NewsWire -- SUNSET ISLAND GROUP, INC. (OTCQB: SIGO) announced today that the company's subsidiary, VBF Brands, received its Provisional Annual License for cannabis cultivation. The license was issue on March 15, 2019 and expires on March 15, 2020. Provisional licenses act as a bridge between state temporary and annual cultivation licenses. A provisional license will act in the same manner as an annual license. The State of California has issued only 2 provisional licenses for cultivation for the County of Monterrey and only 156 within the entire State of California.
The Company has been focusing on completing the licensing process. Now that has been completed, the Company can focus on completing the audit for 2017. The Company expects the 10-K for 2017 to be filed within 4 weeks and the remaining 10-Qs and 10-K to be filed shortly thereafter.
Notice Regarding Forward-Looking Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate.
Source: Sunset Island Group, Inc.

[toomorrow]

$TGLO - Delfin Midstream project moving ahead. Expect R/M announcement any day.

http://www.reuters.com/article/usa-china-lng/first-u-s-floating-lng-project-to-move-ahead-despite-china-trade-war-partner-idUSL5N20U04Y

[toomorrow]

$VYST - FIRST INSTITUTIONAL INVESTOR ON BOARD, UNHEARD OF FOR OTC. INVESTOR PURCHASED AT .15 PER SHARE AND ALSO CLEARED DEBT.
THIS STOCK IS HEADED FOR DOLLAR LAND AND NASDAQ.

[toomorrow]

$TGLO Delfin purchased this shell to reverse merge into pending final investment decision by partner Golar. In the past 6 months, former Golar executives have joined Delfin as CEO and COO and other positions. Dirt cheap Lotto play here. Delfin hold pipeline and permits for floating LNG in Gulf of Mexico. Major announcement expected very soon. . .

[toomorrow]

$VYST - Merger/consolidation of Rotman's Furniture ($35M annual sales) about to drop any day. Debt being paid off. Nasdaq bound by Oct. this year. Will be dollars. Perform some DD and thank me later.

[toomorrow]

$RELI Reverse Merger, assets being added, several deals about to close. Nasdaq bound by end of 2019. Price will be dollars soon. A little DD and you'll be thanking me later.

[ash111]

Upcoming Bitcoin ETF. never been so close as of today. RIOT MARA DPW OSTK

[Eagle1]

MRKR: Billionaire Baker Brothers Quietly Back Marker Therapeutics (NASDAQ: MRKR)
The Baker Brothers, many of which believe have the Midas Touch in the biotech world, invested $5.4 million
October 31, 2018
https://emerginggrowth.com/billionaire-baker-brothers-quietly-back-marker-therapeutics-nasdaq-mrkr/

[WallStreetSTTA]

MASSIVE NEWS OUT ON MNKD!!!

UTHR 8K FILLING OUT AND MNKD ANNOUNCE THE CLOSING FOR $105,000,000 LICENSING DEAL BETWEEN BOTH COMPANIES

https://twitter.com/bdailystocks/status/1052147650177318913

http://stocknewsflow.com/1082554_000110465918062202_0001104659-18-062202

[TheFinalCD]

OHGI .22

was just .65, strong close on good volume yesterday, chart is setting up
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141894884&txt2find=ohgi

[Eagle1]

TPIV made a Bullish moved EOD yesterday. Looking for a continuation.

Merger with Market Thereputics in process now.

[buckiii2]

CRMD. http://www.analystratings.com/articles/h-c-wainwright-sticks-to-their-buy-rating-for-cormedix-inc/

[WallStreetSTTA]

AWESOME NEW ARTICLE ON BPMX https://tradingfam.com/bpmx-analysis-of-main-catalysts/

[buckiii2]

CRMD. Watch unusual volume. Supposedly data coming?

[georgejjl]

AVXL up over 31% Monday June 4, 2018



https://finance.yahoo.com/quote/AVXL?p=AVXL

Good luck and GOD bless,

George

[faxedreceipts]

What about Bob?

[georgejjl]

Good price movement and good volume right before the close of trading today Tuesday May 15, 2018

https://www.nasdaq.com/symbol/ipix/interactive-chart

Good luck and GOD bless,

George

[Pennybuster]

$IGNG Ceo Imaging3, Inc. -MoneyTV with Donald Baillargeon

via @YouTube #stocks #biotechs #smallcaps #3dimaging #pennystocks #stockmarket #otcqb

[TheFinalCD]

yooooo BURP........low floaters are the TREND, and KBSF is one of the lowest MICRO floats
https://finviz.com/quote.ashx?t=KBSF&ty=c&ta=1&p=d


1.69m OS
660k float


just like CLWT

watch it!!!!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140527035

[buckiii2]

Preliminary Results from Quell Chronic Low Back Pain Study to be Presented at World Institute of Pain World Congress
Globe Newswire FOLLOW
May 03, 2018 11:00am Comments
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ:NURO), today reported that preliminary results from a study of Quell® wearable pain relief in chronic low back pain will be presented at the 9th World Congress of the World Institute of Pain in Dublin, Ireland May 9-12, 2018.

The study was conducted by Dr. Robert Jamison and his colleagues at the Brigham and Women's Hospital Pain Management Center in Boston, MA. The poster presentation is titled "Efficacy of high-frequency transcutaneous electrical nerve stimulation for chronic low back pain: does hypersensitivity matter?" and includes the following key findings:

Subjects in the experimental (Quell) group demonstrated reduced pain intensity compared to control subjects.
Subjects in the experimental group exhibited reduced pain interference with function and pain catastrophizing compared to the control group.
Subjects in the experimental group with greater sensitivity on quantitative sensory testing had more disability and higher Quell use, but sensitivity did not predict pain outcomes.
Subjects in the experimental group used their device 381 ± 353 hours during the study.
The study was a three-month single site, controlled, randomized clinical trial. A total of 68 adult patients with a primary complaint of chronic low back pain were enrolled and randomized with equal probability to treatment with the Quell device or "treatment-as usual." Study subjects averaged 46.2 ± 2.7 years of age. All subjects used a smartphone app developed by the Pain Management Center that helps patients document and manage their pain. Outcome measures included the Brief Pain Inventory, the Pain Catastrophizing Scale, the Pain Disability Index and the Hospital Anxiety and Depression Scale. All subjects were given Quantitative Sensory Testing at baseline.

According to the Centers for Disease Control and Prevention (CDC), low back pain is the second most common cause of disability in US adults. The incidence of low back pain is as high as 12 percent of the general population at any given point in time, and nearly 25 percent of US adults report having had it at some point over any one-month period. The condition has a significant economic impact, with total costs estimated to be up to $200B annually. For those with chronic low back pain (low back pain persisting for three or more months), there are few accepted treatments that do not involve prescription medication, manipulation, invasive procedures, or surgery.

"Chronic low back pain is a major health problem and represents a natural application for Quell," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "The preliminary results from this study led by Dr. Robert Jamison are encouraging and we look forward to formal publication of the study findings."

[buckiii2]

AKAO. https://www.smarteranalyst.com/research-analysts/healthcare-analyst-news/achaogen-akao-fdas-briefing-documents-mean-wednesdays-big-adcom-meeting-h-c-wainwright-weighs/

[buckiii2]

AKAO. This guy bought more. https://ih.advfn.com/p.php?pid=nmona&article=77291150&symbol=AKAO

[buckiii2]

CATB up AH on news

[buckiii2]

AKAO. 15%. https://ih.advfn.com/p.php?pid=nmona&article=77246311&symbol=AKAO

[buckiii2]

AKAO insider buys. https://ih.advfn.com/p.php?pid=nmona&article=77242509&symbol=AKAO

[bUrRpPPP!]

NBRV Sheff made some bullish comments last night.....

Sheff @SheffStation
11h
Replying to @tgtxdough

$NBRV..has a really good chance of success in their second ph 3 study but what I would like to see is a tighter Timeframe around data in the spring that would help folks to have a better risk/reward when trading it around the data.

[georgejjl]

OXBDF

Is there something driving these recent spikes in stock price?

https://finance.yahoo.com/quote/OXBDF?p=OXBDF

Why are insiders buying recently?

Two $100 million dollar contracts with pharmaceutical companies.

https://www.reuters.com/article/us-oxford-biomedica-gene-therapy/oxford-biomedica-wins-second-100-million-gene-therapy-contract-idUSKCN1FZ0P4

Good luck and GOD bless,

George

[buckiii2]

EYES. ANNUAL MEETING OF THE STOCKHOLDERS
May 16, 2018

[buckiii2]

OPK. Does this CEO buy stock every day or so? https://ih.advfn.com/p.php?pid=nmona&article=77172125&symbol=OPK

[buckiii2]

EDEN PRAIRIE, Minn., April 12, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc.(NASDAQ:CHFS) announced today its commercial expansion into the Hong Kong market through its Asia distributor, Transmedic. Further, Transmedic has confirmed its first commercial orders for both Singapore and Hong Kong.

[TheFinalCD]

VHC Wins!! suit against ""Apple"" (AAPL)

https://www.schaeffersresearch.com/content/news/2018/04/11/virnetx-stock-booms-on-big-apple-payout

Apple Must Pay $502.6 Million to VirnetX, Federal Jury Rules
https://www.bloomberg.com/news/articles/2018-04-10/apple-owes-502-6-million-to-virnetx-says-federal-jury-in-texas

$VHC willfullness trial currently in session vs $AAPL today. This could bring an extra $250MM minimum ON TOP of the $502MM decided yesterday

https://stocktwits.com/illmighty/message/119573068

4.50

[buckiii2]

AVEO insider buy. https://ih.advfn.com/p.php?pid=nmona&article=77148381&symbol=AVEO

[buckiii2]

ARQL. Upgrade to out perform by Leernik. 15 target. Presents at AACR next week.

[buckiii2]

ZIOP finally moving up. FYI they had a meeting with Jefferies yesterday.

[buckiii2]

CRMD watch. 024.2

[buckiii2]

NURO. NueroMetrix, Inc.: An Interesting Micro-Cap Flyer? https://seekingalpha.com/article/4160264?source=ansh $NURO, $GSK

[buckiii2]

ARQL. FYI this is on ST but I cannot find a press release on it. ArQule receives EU Orphan designation for Miransertib for treatment of Proteus syndrome (through sponsor QRC Consultan…

[TheFinalCD]

PTI 6.83=$$$

[TheFinalCD]

PTI 5.88 dip after hit 6.93 p/m off news

Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
https://finance.yahoo.com/news/proteostasis-therapeutics-announces-fda-grants-200500750.html

[buckiii2]

ArQule, Inc. (ARQL) Shares Bought by BVF Inc. IL
Posted by Nicole Wilson on Mar 11th, 2018
BVF Inc. IL lifted its position in ArQule, Inc. (NASDAQ:ARQL) by 122.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,436,912 shares of the biotechnology company’s stock after acquiring an additional 9,036,784 shares during the period. ArQule comprises approximately 3.3% of BVF Inc. IL’s holdings, making the stock its 10th largest position. BVF Inc. IL owned approximately 0.19% of ArQule worth $27,121,000 at the end of the most recent reporting period.

[buckiii2]

DCAR. 6m private placement.